Australian-based biopharmaceutical company Immuron has closed enrolment in the Phase II clinical trial of its IMM-124E to treat non-alcoholic steatohepatitis (NASH) patients.

IMM-124E is developed to act against LPS antigens through its binding and neutralising activity.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug also consists of adjuvants that enhance regulatory T-cells to inhibit inflammation in target organs.

It is believed that the anti-LPS activity minimises the LPS challenge to the liver and down-regulates the T regulatory cell population in chronic inflammation and other metabolic defects associated with NASH.

The multi-centre, double blind, randomised Phase II trial will evaluate the safety and efficacy of IMM-124E when compared to placebo after six months of treatment.

"This significant milestone is a result of the efforts of many over the past three years."

Conducted in the US, Australia, and Israel, Immuron has enrolled a total of 120 randomised patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Immuron chief executive officer Thomas Liquard said: “This significant milestone is a result of the efforts of many over the past three years.  

"IMM-124E has a unique multifactorial mechanism of action (MOA) that we believe possesses a unique combination of safety and efficacy attributes, which have the potential to greatly improve outcomes for NASH patients worldwide.”

It is estimated that the topline results of the Phase II trial will be reported in the second half of this year.

Immuron develops and commercialises oral immunotherapeutics for the treatment of many gut mediated diseases. The firm's safe technology platform is claimed to facilitate a shorter development therapeutic cycle.